LIF and neoplasm: In pancreatic cancer, a blockade of LIF:LIFR:STAT3 signaling resulted in a decrease in the expression of CSC-associated markers (CD133, CD24, and CD44), a reduction in tumor initiation and formation, and an overall less aggressive phenotype [168].